Efficacy of Anti-Interleukin-1 Receptor Antagonist Anakinra (Kineret®) in a Case of Refractory Sweet's Syndrome

被引：67

作者：

Kluger, Nicolas ^{[1
,2
,3
,4
]}

Gil-Bistes, Deborah ^{[1
]}

Guillot, Bernard ^{[1
]}

Bessis, Didier ^{[1
]}

机构：

[1] Univ Montpellier 1, Serv Dermatol, Hop St Eloi, CHU Montpellier, Montpellier, France

[2] Univ Helsinki, Helsinki Univ Cent Hosp, Dept Dermatol, Inst Clin Med,Skin & Allergy Hosp, Helsinki, Finland

[3] Univ Helsinki, Helsinki Univ Cent Hosp, Dept Allergol, Inst Clin Med,Skin & Allergy Hosp, Helsinki, Finland

[4] Univ Helsinki, Helsinki Univ Cent Hosp, Dept Venereol, Inst Clin Med,Skin & Allergy Hosp, Helsinki, Finland

来源：

DERMATOLOGY | 2011年 / 222卷 / 02期

关键词：

Sweet's syndrome; Neutrophilic dermatosis; Anakinra; Interleukin-1 receptor antagonist; TUMOR-NECROSIS-FACTOR; ULCERATIVE-COLITIS; CROHNS-DISEASE; INTERLEUKIN-1; PATHOGENESIS; ETANERCEPT; ARTHRITIS; IL-1;

D O I：

10.1159/000326112

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Sweet's syndrome is a neutrophilic dermatosis characterized by fever, an elevated neutrophil count, and painful erythematous cutaneous lesions. Histopathological analysis reveals a neutrophilic dermal infiltrate. Systemic corticosteroid therapy remains the mainstay of treatment. We report the case of a 66-year-old male patient who had a 5-year history of Sweet's syndrome refractory to various conventional treatments. Anti-inter-leukin-1 receptor antagonist anakinra was initiated and this resulted in a dramatic clinical and biological improvement. Anakinra is a promising treatment for neutrophilic dermatoses and sheds light on the interleukin-1/inflammasome pathway as central in the physiopathology of neutrophilic dermatosis. Copyright (C) 2011 S. Karger AG, Basel

引用

页码：123 / 127

页数：5

共 21 条

[1] Etanercept Treatment in Sweet's Syndrome with Inflammatory Arthritis
Ambrose, Nicola L.
Tobin, Anne Marie
Howard, Donough
[J]. JOURNAL OF RHEUMATOLOGY, 2009, 36 (06) : 1348 - 1349
[2] Bourke JF, 1996, BRIT J DERMATOL, V134, P705, DOI 10.1111/j.1365-2133.1996.tb06975.x
[3] Coexistence of pyoderma gangrenosum and sweet's syndrome in a patient with ulcerative colitis
Castro-Fernandez, Manuel
Sanchez-Munoz, Diego
Ruiz-Granados, Elena
Merchante, Nicolas
Corzo, Juan
[J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 (12) : 2865 - 2866
[4] Primer:: inflammasomes and interleukin 1β in inflammatory disorders
Church, Leigh D.
Cook, Graham P.
McDermott, Michael F.
[J]. NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2008, 4 (01): : 34 - 42
[5] Sweet's syndrome: A review of current treatment options
Cohen P.R.
Kurzrock R.
[J]. American Journal of Clinical Dermatology, 2002, 3 (2) : 117 - 131
[6] Neutrophilic Dermatoses A Review of Current Treatment Options
Cohen, Philip R.
[J]. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2009, 10 (05) : 301 - 312
[7] Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome
Delluc, A.
Limal, N.
Puechal, X.
Frances, C.
Piette, J. C.
Cacoub, P.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (02) : 278 - 278
[8] Blocking IL-1 in systemic inflammation
Dinarello, CA
[J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 201 (09) : 1355 - 1359
[9] Sweet's syndrome: Is the pathogenesis mediated by helper T cell type 1 cytokines?
Giasuddin, ASM
El-Orfi, AHAM
Ziu, MM
El-Barnawi, NY
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1998, 39 (06) : 940 - 943
[10] IS THE PATHOGENESIS OF SWEETS SYNDROME MEDIATED BY INTERLEUKIN-I
GOING, JJ
[J]. BRITISH JOURNAL OF DERMATOLOGY, 1987, 116 (02) : 282 - 283

← 1 2 3 →